STAT+: ARPA-H to invest $62 million to develop FDA-authorized AI to help treat heart failure — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- ARPA-H announced a $62.7 million commitment through its new ADVOCATE program to develop AI agents that direct heart failure treatment, with the goal of producing partially autonomous FDA-authorized devices.
- The funded devices would assess symptom severity, prescribe drugs, and order lab tests, according to the program's stated objectives.
- First-year funding totals $33.7 million, with the remainder potentially renegotiated up or down; ARPA-H may still fund additional teams beyond the inaugural batch.
- Atman Health, UpDoc, Tempus AI, Stanford University, Duke University, and Kaiser Permanente received the first round of awards, announced Wednesday.
- The program targets the 6.7 million Americans living with heart failure, many of whom lack access to optimal specialist care—particularly in rural and other underserved settings.
Why it matters: Six named companies and university teams are already funded to build AI that doesn't merely flag problems but prescribes medications and orders labs, targeting a documented access gap for 6.7 million heart failure patients; $33.7 million flows this year, with FDA authorization baked into the program's stated goal.
Ask SkimNews
